Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
Vijay Ramakrishnan(Mayo Clinic in Arizona), Shaji Kumar(Mayo Clinic in Arizona)
Cited by 36
Related Papers
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
|Mayo Clinic Proceedings|2009|625
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
|Oncotarget|2016|24
Three‐dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma
|American Journal of Hematology|2024|8